Adamas Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 25.9 million compared to USD 20.18 million a year ago. Net loss was USD 19.52 million compared to USD 11.92 million a year ago. Basic loss per share from continuing operations was USD 0.43 compared to USD 0.42 a year ago. Diluted loss per share from continuing operations was USD 0.43 compared to USD 0.42 a year ago. For the nine months, revenue was USD 67.18 million compared to USD 53.45 million a year ago. Net loss was USD 44.44 million compared to USD 39.13 million a year ago. Basic loss per share from continuing operations was USD 1.05 compared to USD 1.39 a year ago. Diluted loss per share from continuing operations was USD 1.05 compared to USD 1.39 a year ago.